DDInter1144 DDInter178
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Melphalan {u} (Compound) resembles {v} (Compound) L-Phenylalanine
Melphalan {u} (Compound) resembles {v} (Compound) Levodopa
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
Melphalan {u} (Compound) binds {v} (Gene) SLC7A5
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
Melphalan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Melphalan {u} (Compound) causes {v} (Side Effect) Radiation myelopathy
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Melphalan (Compound) resembles L-Phenylalanine (Compound)
Melphalan (Compound) resembles Levodopa (Compound)
Melphalan (Compound) treats ovarian cancer (Disease)
Melphalan (Compound) binds SLC7A5 (Gene)
Melphalan (Compound) upregulates DDB2 (Gene)
Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Melphalan (Compound) causes Radiation myelopathy (Side Effect)
Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab